课题基金 / 基金详情

项目摘要

项目成果

Erik de Leeuw的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The prevalence of resistant bacterial pathogens is rendering current antibiotics ineffective, and making it essential that new drugs be developed to fight infection. Defensins are antimicrobial peptides that protect man against bacterial and viral infections and have a wide range as potential anti-infective therapeutics. This proposal identifies Lipid II, an essential precursor in bacterial membrane biogenesis, as a potential target of defensin antibacterial activity for the first time. The overall objective of our study is to define functional and structural interactions between defensins and Lipid II. In the long term, we aim to apply the knowledge gained in our research towards the development of defensin-based antibiotic compounds targeting Lipid II to combat Gram-positive pathogenic infections. PUBLIC HEALTH RELEVANCE: The escalating frequency of antibiotic resistant infections combined underscores the critical need to develop novel antibiotics. This project describes for the first time the interaction between defensins, naturally occurring antimicrobial compounds in humans and Lipid II, essential in the formation of bacterial membranes. Our research sheds new light on how defensins kill bacteria and is an important first step towards the development of these natural peptides as novel, effective antibiotic agents to combat infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Basis of Human Defensins as Novel Lipid II Binding Peptide Antibiotics
  • 批准号:
    8320100
  • 项目类别:
  • 资助金额:
    $19.19万
  • 财政年份:
    2011
  • 负责人:
    Erik de Leeuw
  • 依托单位:
海外基金